Current therapeutic treatments for cardiovascular disease and genetic NLRP3‐linked diseases such as CAPS are therapies targeting IL‐1β, including the neutralising monoclonal antibody canakinumab, the soluble IL‐1 receptor rilonacept or recombinant IL‐1 receptor antagonist anakinra.22 The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.